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ABSTRACT
Hypoxia inducible transcription factors (HIFs) are the main regulators of adaptive 
responses to hypoxia and are often activated in solid tumors, but their role in leukemia 
is less clear. In acute myeloid leukemia (AML), in particular, controversial new findings 
indicate that HIF-1a can act either as an oncogene or a tumor suppressor gene, and 
this may depend on the stage of leukemia development and/or the AML sub-type.
In this study, we find that HIF-1a promotes leukemia progression in the acute 
monocytic leukemia sub-type of AML through activation of an invasive phenotype. 
By applying a list of validated HIF-1a-target genes to different AML sub-types, we 
identified a HIF-1a signature that typifies acute monocytic leukemia when compared 
with all other AML sub-types. We validated expression of this signature in cell lines 
and primary cells from AML patients. Interestingly, this signature is enriched for 
genes that control cell motility at different levels. As a consequence, inhibiting HIF-
1a impaired leukemia cell migration, chemotaxis, invasion and transendothelial 
migration in vitro, and this resulted in impaired bone marrow homing and leukemia 
progression in vivo. Our data suggest that in acute monocytic leukemia an active 
HIF-1a-dependent pro-invasive pathway mediates the ability of leukemic cells to 
migrate and invade extramedullary sites and may be targeted to reduce leukemia 
dissemination.
INTRODUCTION
Acute myeloid leukemia (AML) represents almost 
80% of all adult acute leukemia and is a heterogeneous 
disorder of the hematopoietic system caused by a number 
of genetic alterations and characterized by uncontrolled 
cell proliferation, escape from apoptosis and block of 
myeloid differentiation [1, 2]. The resulting growth 
of a clonal population of neoplastic cells in the bone 
marrow and blood leads to loss of normal hematopoietic 
functions.
Acute monocytic leukemia is the M5 sub-type of 
acute myeloid leukemia (AML-M5) according to the 
French-American-British (FAB) classification [3, 4]. 
AML-M5 is characterized by a differentiation arrest of the 
myelo-monocytic lineage at the monoblast, promonocytic 
or monocytic stage and constitutes 5-10% of all AML 
cases in adults [5, 6]. Clinically, AML-M5 is characterized 
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by hyperleukocytosis, intravascular coagulation and 
a propensity to infiltrate extramedullary sites [7–9]. 
Beyond the phenotypic and clinical characterization, 
however, AML-M5 encompasses a class of genetically 
heterogeneous diseases with different mutations and 
chromosomal translocations. Among them, frequent 
genetic aberrations include translocations involving 
the MLL gene on chromosome 11q23, and mutations 
in NPM1, FLT3, NRAS and DNMT3A [10–13, 9], with 
NPM1 mutations associated with favorable prognosis, and 
FLT3 and DNMT3A mutations and MLL rearrangements 
associated with adverse prognosis [14].
Hypoxia inducible transcription factors (HIFs) are 
the main regulators of adaptive responses to low oxygen 
concentrations and are often up-regulated in solid tumors 
as a result of intra-tumoral hypoxia or activation of specific 
oncogenic pathways [15]. HIFs regulate a vast array of 
cellular responses in tumors, including metabolism, cell 
migration, invasion, metastasis and angiogenesis, and their 
expression often correlates with poor clinical outcome and 
patients survival [15–19].
In leukemia, the study of HIF factors has lagged 
behind for a number of years, and only recently their 
expression and function are beginning to be characterized. 
In AML in particular, a number of studies with human 
cells and xenograft mouse models have recently suggested 
that HIF-1α and HIF-2α play pro-leukemogenic functions 
by regulating leukemia progression and maintenance of 
leukemia initiating cells (LICs). As a consequence, their 
inhibition leads to leukemia de-bulking and eradication 
[20–25]. In apparent contrast with these results however, 
recent evidence obtained in mouse models of AML suggests 
that genetic deletion of Hif-1α or Hif-2α may rather 
promote development and/or maintenance of LICs in the 
presence of specific leukemogenic mutations, such as MLL 
rearrangements or AML1-ETO, while having no apparent 
effect on the progression of established leukemia [26–27]. 
Therefore, further characterization of the role of these 
factors in different AML sub-types is needed to reconcile 
these contrasting results and conclusively elucidate the 
potential of HIF inhibition for leukemia treatment.
Here, to better elucidate the involvement of hypoxia 
signaling in distinct AML sub-types, we applied a 
previously described list of bona fide HIF-1α target genes 
[24, 28] to the transcriptomic profiles of AML patients 
sub-categorized according to the FAB classification. We 
found that besides AML-M3, which we had previously 
identified as an AML sub-type with specific up-regulation 
of hypoxia signaling [24, 28], AML-M5 patients display 
specific up-regulation of a number of HIF-1α-target genes 
implicated in cell migration, invasion and transendothelial 
migration. In accordance with these data, inhibition 
of HIF-1α in a number of AML-M5 cell lines impairs 
leukemia motility and delays leukemia propagation in 
vivo. Therefore, our data indicate that HIF-1α exerts 
context-specific oncogenic functions in AML, with a pro-
invasive role in AML-M5 that may be targeted to reduce 
leukemia dissemination.
RESULTS
Acute monocytic leukemia is typified by a 
HIF-1α-dependent signature enriched in genes 
promoting cell motility and invasion
We have previously reported that in acute 
promyelocytic leukemia (APL, AML-M3) HIF-1α 
inhibition delays leukemia progression and synergizes 
with retinoic acid in eradicating LICs [24–29]. However, 
recent studies have suggested that in AML HIF-1α may 
act as an oncogene or a tumor suppressor gene depending 
on the AML sub-type [30]. Here, to help elucidate the 
function of HIF-1α in other AML sub-types besides APL, 
we selected a list of validated HIF-1α-target genes [24–28] 
and assessed the ability of this signature to typify AML 
FAB sub-types.
Amongst different AML, the FAB sub-type that was 
most significantly discriminated by Prediction Analysis 
of Microarray (PAM) was AML-M3, with a sensitivity 
of 0.800 and an accuracy of 0.964, thus confirming our 
previous results about the involvement of HIF-1α in APL 
[24–28]. Following AML-M3, PAM analysis provided the 
best recall for AML-M5 with a value of 0.727 (overall 
accuracy = 0.846), and a subset of 28 informative HIF-1α-
target genes that were found most distinctive. The majority 
of these genes (21 out of 28, in red in Figure 1A) were 
found up-regulated in M5 patients compared to patients 
with other types of AML, while only 7 genes were down-
regulated (in blue in Figure 1A). All AML samples were 
visualized in Figure 1B according to the expression of the 
28 informative genes by multidimensional scaling.
Interestingly, the 21 HIF-1α-target genes up-
regulated in AML-M5 patients were found enriched 
for the Gene Ontology term cell motion (adj. p-value = 
2.40e-02), and a number of genes contained in this list 
are known mediators of cell migration, invasion and 
transendothelial migration not only in solid tumors 
but also in haematological malignancies (Figure 1A). 
LGALS1 belongs to the galectins family of beta-
galactoside-binding proteins that modulate cell-cell and 
cell-matrix interactions, its expression correlates with 
tumor cell motility and invasiveness [31, 32], and is up-
regulated in leukemia [33–35]. S100A4 (S100 Calcium-
Binding Protein A4) is a protein involved in cell motility, 
invasion, and tubulin polymerization [36]; it is implicated 
in tumor metastasis [37, 36] and maintenance of cancer 
stem cells [38]. CAPG is a member of the gelsolin/villin 
family of actin-regulatory proteins that promotes cell 
migration and is over-expressed in different solid tumors 
[39, 40]. ITGB2 (integrin beta chain 2) regulates cell 
adhesion and signaling in combination with different alpha 
chains, and has been associated with the formation of 
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invadosomes that facilitate leukemia cell invasion through 
transendothelial migration [41]. CXCR4, the receptor of 
stromal cell-derived factor-1 (SDF-1α), is up-regulated in 
different leukemic contexts and is an important regulator 
of chemotaxis towards protective niches in the bone 
marrow [42, 43].
In addition, within the top 10 genes up-regulated 
in AML-M5, we also found CDKN1A, which encodes 
a cyclin-dependent kinase inhibitor that promotes 
maintenance of leukemia stem cells [44], and the ZEB2 
transcription factor, a master regulator of epithelial to 
mesenchymal transition [45] that also has been implicated 
in cancer and leukemia stem cell maintenance [46–48].
In order to validate the data obtained by in silico 
analysis, we measured the expression of the top up-
regulated HIF-1α-target genes in primary leukemic bone 
marrow samples from AML patients diagnosed and treated 
at San Raffaele Hospital. Real time PCR analysis confirmed 
up-regulation of LGALS1, S100A4, CAPG, ITGB2, 
CDKN1A, ZEB2 and CXCR4 in AML-M5 patients 
compared with other AML FAB sub-types (Figure 2A).
To corroborate these findings in cell models more 
amenable to in vitro manipulation we analyzed expression 
of LGALS1, S100A4, CAPG, ITGB2, CDKN1A, ZEB2 
and CXCR4 in the AML cell lines: KG-1, Kasumi-1, HL-
60 and NB4 representative of FAB sub-types from M0 to 
M3, and the M5 cell lines MOLM-13, THP-1 and Mono 
Mac 6. Expression analysis confirmed up-regulation of all 
genes in cell lines of the M5 FAB sub-type compared with 
other cell lines (Figure 2B).
Figure 1: A HIF-1α sub-signature regulating cell motility acts as an AML-M5 class predictor. A list of 28 genes that 
recognize 72% of M5 samples was selected among HIF-1α target genes using PAM algorithm A. Ranked list of the genes used in the 
classification. B. Multidimensional scaling on 195 AML samples using the signature obtained by the PAM classifier (M5 samples in light 
gray, non-M5 samples in black).
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Figure 2: Validation of the top up-regulated HIF-1α-target genes in AML-M5 cells. A. Real-time PCR analysis of LGALS1, 
S100A4, CAPG, ITGB2, CDKN1A, ZEB2 and CXCR4 in primary bone marrow samples from M5 (n=7) and other FAB sub-types (n=17) 
AML patients. Data are represented as mean values ± s.e.m. B. Real-time PCR analysis of LGALS1, S100A4, CAPG, ITGB2, CDKN1A, 
ZEB2 and CXCR4 in human M5 cell lines (n=3) and other AML cell lines (n=4). Data are represented as mean values ± s.e.m of three 
independent experiments.
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In agreement with mRNA data, increased expression 
of selected genes, such as LGALS1, ITGB2 and CXCR4 
was observed in AML-M5 cell lines also at the protein 
level, either by western blotting or surface expression 
(Figure 3A–3D). Interestingly, we observed that the 
HIF-1α protein is expressed in normoxic conditions in 
a number of AML cell lines, with highest expression in 
NB4 cells, representative of AML-M3, followed by M5 
cell lines (Figure 3E and 3F). These differences are not 
mirrored by corresponding mRNA levels (Figure 3G), 
thus suggesting that HIF-1α is up-regulated through post-
transcriptional mechanisms yet to be identified in AML 
cells of different origin.
Taken together, these results indicate that in the 
M5 sub-type of AML a HIF-1α-dependent signature that 
regulates migration of leukemic cells is up-regulated as 
compared to other types of AML.
HIF-1α silencing impairs cell migration and 
invasion in AML-M5 leukemic cells
To evaluate the function of HIF-1α towards 
controlling the expression of genes involved in cell 
motion in AML-M5, HIF-1α was stably down-regulated 
in MOLM-13 cells using validated shRNAs [24, 49]. 
HIF-1α silencing led to about 50% reduction in HIF-1α 
expression at mRNA and protein level (Figure 4A–4C). 
Accordingly, the expression of common HIF-1α-target 
genes like BNIP3 and GLUT1 was significantly reduced 
upon HIF-1α silencing (Figure 4C). In addition, the top 
up-regulated HIF-1α-target genes in AML-M5 were all 
down-regulated after HIF-1α inhibition (Figure 4D), thus 
indicating that also in the context of AML-M5 these genes 
are regulated by HIF-1α.
We next tested the functional consequences of HIF-
1α down-regulation. Proliferation rates and basal apoptosis 
were not affected by chronic HIF-1α silencing in MOLM-
13 cells (Supplementary Figure 1A and B). As HIF-1α 
inhibition led to down-regulation of genes involved in 
migration, chemotaxis, invasion and transendothelial 
migration, the motile and invasive phenotypes of MOLM-
13 cells were tested after HIF-1α silencing. Both basal and 
SDF-1α-induced cell migration were impaired in HIF-1α 
down-modulated cells (Figure 4E and 4F), according with 
CXCR4 inhibition. In addition, cell invasion through 
matrigel and transendothelial migration through a HUVEC 
monolayer were also significantly impaired upon reduced 
HIF-1α expression (Figure 4G and 4H), consistently with 
down-regulation of LGALS1, S100A4 and ITGB2 that 
mediate invasive and infiltrating phenotypes.
To substantiate our data in another relevant context, 
we inhibited HIF-1α in a second AML-M5 cell line, THP-
1. Similarly to MOLM-13 cells, down-regulation of HIF-
1α and common target genes BNIP3 and GLUT1 (Figure 
5A) was accompanied by inhibition of HIF-1α-target 
genes involved in migration, invasion and self-renewal in 
THP-1 cells (Figure 5B). Accordingly, HIF-1α silencing 
resulted in inhibition of basal migration, SDF-1α-mediated 
chemotaxis, cell invasion and transendothelial migration 
(Figure 5C–5F). To understand if regulation of the motile 
phenotype by HIF-1α occurs specifically in AML-M5, 
we stably silenced HIF-1α in a cell line representative 
of AML-M2 (Kasumi-1 cells). Interestingly, although as 
expected also in this cell line HIF-1α down-regulation 
led to inhibition of the target genes implicated in cell 
motility, albeit more modestly (Figure 5G), basal and 
SDF-1α-mediated cell migration were not affected by 
HIF-1α silencing (Figure 5H and data not shown). This 
indicates that the function of HIF-1α towards inducing cell 
motility may be particularly relevant in AML-M5, which 
is consistent with the evidence that the genes that we have 
analyzed are expressed at higher levels in this AML sub-
type (Figure 2 and 3).
Taken together, these data indicate that HIF-1α 
activates a pro-invasive gene signature in acute monocytic 
leukemia that leads to increased motility, invasion and 
transendothelial migration, and inhibition of HIF-1α 
impairs important functions of monocytic leukemia blasts.
Acute HIF-1α silencing recapitulates HIF-1α 
chronic silencing
To corroborate the findings obtained with HIF-
1α chronic silencing, and to establish whether more 
pronounced and acute inhibition of HIF-1α may further 
impinge on the functions of AML-M5 leukemic cells, we 
next used the RNA antagonist EZN-2968, a locked nucleic 
acid-modified oligonucleotide (LNA-ON) targeting HIF-
1α, and its control LNA-ON EZN-3088 [50].
EZN-2968 transfection led to a reduction of more 
than 90% of HIF-1α mRNA levels in AML-M5 MOLM-
13, THP-1 and Mono Mac 6 cells (Figure 6A, 6D and 
6G). In accordance with the data previously obtained upon 
stable silencing of HIF-1α (Figure 4D and 5B), acute HIF-
1α silencing resulted in similar down-regulation of the top 
AML-M5 HIF-1α-target genes in the three cells lines, 
with the notable exception of LGALS1 and CDKN1A, 
which were consistently found not regulated or up-
regulated respectively (Figure 6A, 6D and 6G). While 
the lack of LGALS1 regulation in conditions of acute 
HIF-1α silencing may indicate that LGALS1 is a late-
response gene, or that it is indirectly regulated by HIF-1α 
in this context, CDKN1A up-regulation correlated with 
decreased proliferation and increased apoptosis when HIF-
1α was strongly inhibited, which was not observed upon 
milder and chronic HIF-1α silencing (please, compare 
Supplementary Figure 1A and B with Supplementary 
Figure 3B and C). As HIF-1α is an essential regulator 
of anaerobic glycolysis, AML-M5 neoplastic cells may 
be addicted to minimal levels of HIF-1α expression for 
proliferation and survival, and acute and strong HIF-1α 
inhibition obtained with EZN-2968 may be detrimental 
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Figure 3: HIF-1α protein expression is up-regulated in AML-M5 cell lines. A. Immunoblot of LGALS1 in human M5 cell lines 
(n=3) and other AML cell lines (n=4). B. Quantification of immunoblot in (A). Graph represents the ratio between LGALS1 over β-actin. 
C. Flow cytometric analysis of ITGB2 and CXCR4 positive cells (percentage of + cells). Graph represents the relative expression of ITGB2 
and CXCR4 in human M5 cell lines over other AML cell lines. Data represent mean values ± s.e.m of three independent experiments. D. 
MFI (mean fluorescent intensity) of ITGB2 and CXCR4 in human M5 cell lines over other AML cell lines. Data represent mean values 
± s.e.m of three independent experiments. E. Immunoblot of HIF-1α in human M5 cell lines (n=3) and other AML cell lines (n=4). F. 
Quantification of immunoblot in (E). Graph represents the ratio between HIF-1α over β-actin. G. Real-time PCR analysis of HIF-1α in 
human AML cell lines. Data are represented as mean values ± s.e.m of three independent experiments.
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Figure 4: HIF-1α chronic silencing impairs motility of MOLM-13 cells in vitro. A. Immunoblot of HIF-1α in MOLM-13 cells 
transduced with lentiviral vectors carrying control (shCTRL) or HIF-1α-directed shRNA (shHIF-1α). When indicated shCTRL and shHIF-
1α MOLM-13 cells were treated with CoCl2 to increase HIF-1α stability. B. Quantification of immunoblot in (A). Graph represents the ratio 
between HIF-1α over β-actin. C. Real-time PCR analysis of HIF-1α and its target genes BNIP3 and GLUT1 in MOLM-13 cells transduced 
as in (A). Data represent mean values ± s.e.m. of three independent experiments. D. Real-time PCR analysis of LGALS1, S100A4, CAPG, 
ITGB2, CDKN1A, ZEB2 and CXCR4 in shHIF-1α MOLM-13 cells relative to shCTRL cells. Data represent mean values ± s.e.m. of three 
independent experiments. E. Basal migration, expressed as percentage of shHIF-1α MOLM-13 cells relative to shCTRL. Data represent 
mean values ± s.e.m. of three independent experiments. F. SDF-1α induced migration (fold increase) of shCTRL and shHIF-1α MOLM-
13 cells relative to basal migration of their respective control. Data represent mean values ± s.e.m. of three independent experiments. 
G. Basal invasion, expressed as percentage of shHIF-1α MOLM-13 cells relative to shCTRL. Data represent mean values ± s.e.m. of 
three independent experiments. H. Transendothelial migration through a HUVEC endothelial layer, expressed as percentage of shHIF-1α 
MOLM-13 cells relative to shCTRL. Data represent mean values ± s.e.m. of three independent experiments.
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Figure 5: HIF-1α chronic silencing impairs motility of THP-1 cells in vitro. A. Real-time PCR analysis of HIF-1α and its 
target genes BNIP3 and GLUT1 in THP-1 cells transduced with lentiviral vectors carrying control (shCTRL) or HIF-1α-directed shRNA 
(shHIF-1α). Data represent mean values ± s.e.m. of three independent experiments. B. Real-time PCR analysis of LGALS1, S100A4, 
CAPG, ITGB2, CDKN1A, ZEB2 and CXCR4 in shHIF-1α THP-1 cells relative to shCTRL cells. Data represent mean values ± s.e.m. of 
three independent experiments. C. Basal migration, expressed as percentage of shHIF-1α THP-1 cells relative to shCTRL. Data represent 
mean values ± s.e.m. of three independent experiments. D. SDF-1α induced migration (fold increase) of shCTRL and shHIF-1α THP-1 
cells relative to basal migration of their respective control. Data represent mean values ± s.e.m. of three independent experiments. E. Basal 
invasion, expressed as percentage of shHIF-1α THP-1 cells relative to shCTRL. Data represent mean values ± s.e.m. of three independent 
experiments. F. Transendothelial migration through a HUVEC endothelial layer, expressed as percentage of shHIF-1α THP-1 cells relative 
to shCTRL. Data represent mean values ± s.e.m. of three independent experiments. G. Real-time PCR analysis of HIF-1α, LGALS1, 
S100A4, CAPG, ITGB2, CDKN1A, ZEB2 and CXCR4 in Kasumi-1 cells transduced with lentiviral vectors carrying control (shCTRL) or 
HIF-1α-directed shRNA (shHIF-1α). Data represent mean values ± s.e.m. of three independent experiments. H. SDF-1α induced migration 
(fold increase) of shCTRL and shHIF-1α Kasumi-1 cells relative to basal migration of their respective control. Data represent mean values 
± s.e.m. of three independent experiments.
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Figure 6: Acute HIF-1α silencing recapitulates HIF-1α chronic silencing in different AML-M5 cell lines in vitro. A. Real-
time PCR analysis of HIF-1α, LGALS1, S100A4, CAPG, ITGB2, CDKN1A, ZEB2 and CXCR4 in MOLM-13 cells 24 h after transfection 
with EZN-2968 relative to cells transfected with EZN-3088. Data represent mean values ± s.e.m. of three independent experiments. B. 
Basal migration, expressed as percentage of MOLM-13 cells transfected with EZN-2968 relative to cells transfected with EZN-3088. 
Data represent mean values ± s.e.m. of three independent experiments. C. SDF-1α induced migration (fold increase) of EZN-3088 and 
EZN-2968 transfected MOLM-13 cells, relative to basal migration of their respective control. Data represent mean values ± s.e.m. of three 
independent experiments. D. Real-time PCR analysis of HIF-1α, LGALS1, S100A4, CAPG, ITGB2, CDKN1A, ZEB2 and CXCR4 in 
THP-1 cells 24 h after transfection with EZN-2968 relative to cells transfected with EZN-3088. Data represent mean values ± s.e.m. of 
three independent experiments. E. Basal migration, expressed as percentage of THP-1 cells transfected with EZN-2968 relative to cells 
transfected with EZN-3088. Data represent mean values ± s.e.m. of three independent experiments. F. SDF-1α induced migration (fold 
increase) of EZN-3088 and EZN-2968 transfected THP-1 cells, relative to basal migration of their respective control. Data represent mean 
values ± s.e.m. of three independent experiments. G. Real-time PCR analysis of HIF-1α, LGALS1, S100A4, CAPG, ITGB2, CDKN1A, 
ZEB2 and CXCR4 in Mono Mac 6 cells 24 h after transfection with EZN-2968 relative to cells transfected with EZN-3088. Data represent 
mean values ± s.e.m. of three independent experiments. H. Basal migration, expressed as percentage of Mono Mac 6 cells transfected with 
EZN-2968 relative to cells transfected with EZN-3088. Data represent mean values ± s.e.m. of three independent experiments. I. SDF-1α 
induced migration (fold increase) of EZN-3088 and EZN-2968 transfected Mono Mac 6 cells, relative to basal migration of their respective 
control. Data represent mean values ± s.e.m. of three independent experiments.
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to the cells. Importantly, EZN-2968 also impaired cell 
migration, both in basal conditions and upon SDF-1α 
stimulation, in all AML-M5 cell lines tested (Figure 6B, 
6C, 6E, 6F, 6H and 6I).
Taken together these data indicate that acute 
silencing of HIF-1α impairs important pro-leukemogenic 
functions like basal cell migration and chemotaxis of 
AML-M5 cells in vitro and may therefore result in 
impaired leukemia progression or propagation in vivo.
HIF-1α inhibition results in impaired leukemia 
homing and development in a xenograft model of 
acute monocytic leukemia in vivo
To understand whether HIF-1α inhibition led to 
impaired leukemia development and progression in vivo 
we took advantage of a MOLM-13 xenograft model of 
acute monocytic leukemia that mimics human leukemia in 
that mice develop a rapid and fatal acute myeloid leukemia 
localizing to the bone marrow, spleen and peripheral blood 
upon intravenous injections [51].
MOLM-13 cells, transduced with shRNA constructs 
(shCTRL and shHIF-1α) and a lentiviral vector co-
expressing luciferase and ΔNGFR, were transplanted 
intravenously into immunocompromised NSG mice. 
Consistently with down-modulation of CXCR4 (Figure 
4D), cells with reduced expression of HIF-1α showed 
defective bone marrow homing 16 hours after injection 
(Figure 7A). As a consequence, short-term colonization of 
the bone marrow was still impaired 5 days after injection 
(Figure 7B and 7C). However, this difference was 
progressively lost at later time points, and when animals 
were sacrificed because terminally sick no difference in 
leukemia involvement was observed in various organs 
(Supplementary Figure 2A-2C). Accordingly, we did not 
detect any difference in terms of survival of transplanted 
animals (data not shown). However, real time PCR 
analysis of leukemic bone marrow at the end of the 
experiment revealed that HIF-1α silencing was lost in 
vivo (Supplementary Figure 2D). Although sorted for 
GFP expression, injected cells comprised a multi-clonal 
population of cells expressing different levels of GFP 
(and presumably HIF-1α); therefore, it is likely that loss 
of HIF-1α silencing reflects a counter selection of cells 
with lower HIF-1α levels under increased in vivo selective 
pressure.
To establish whether stronger and acute HIF-1α 
silencing may impact more profoundly on leukemia onset 
and progression, luciferase and ΔNGFR co-expressing 
MOLM-13 cells were electroporated with EZN-2968 
and its control oligonucleotide EZN-3088 and injected 
into NSG mice. Interestingly, acute HIF-1α silencing 
led to decreased proliferation and increased apoptosis 
24 hours after in vitro transfection (Supplementary 
Figure 3B and 3C), which was not observed upon 
chronic and milder inhibition (Supplementary Figure 
1). Similar to chronic HIF-1α inhibition, acute silencing 
also resulted in impaired bone marrow homing (Figure 
7D). In addition however, acute silencing of HIF-1α led 
to prolonged inhibition of bone marrow colonization, 
as measured by in vivo luciferase activity at day 5 and 
day 9 from leukemia challenge (Figure 7E–7G), and 
prolonged mice survival (Figure 7H). To better elucidate 
the effect of HIF-1α acute silencing on the dissemination 
of leukemic cells and leukemia colonization in vivo, 
leukemia involvement was analyzed in different organs 
at different time points. 9 days post leukemia challenge a 
significant percentage of MOLM-13 cells transfected with 
control LNA-ON was found in bone marrow and spleen 
of NSG mice, and a smaller percentage also colonized 
liver and lungs (Supplementary Figure 3D). HIF-1α 
silenced cells were in general less prone to engraft and 
colonize not only bone marrow and spleen but also all 
other organs (Supplementary Figure 3D). This difference 
was still maintained 15 days post-leukemia challenge 
(Supplementary Figure 3E), while it was lost when mice 
were sacrificed because terminally sick (Supplementary 
Figure 3F-H). Also, similar to what was observed upon 
chronic HIF-1α down-regulation, HIF-1α inhibition 
in bone marrow leukemic cells was lost at the end of 
experiment upon acute HIF-1α silencing (Supplementary 
Figure 3I), perhaps less surprisingly as oligonucleotide-
mediated inhibition may be lost upon cell division, and 
cells with strong HIF-1α inhibition were found to be prone 
to cell cycle arrest and apoptosis in vitro (Supplementary 
Figure 3B and 3C).
Taken together these data show that hampering HIF-
1α expression in a mouse model of AML-M5 results in 
impairment of bone marrow homing, colonization and 
leukemia progression, thus indicating that in this AML 
context HIF-1α plays oncogenic functions.
DISCUSSION
HIF-1α is a master regulator of cellular responses 
to low oxygen concentrations in both physiological and 
pathological conditions. The role of HIF-1α has been 
extensively studied in solid tumors, where often it has 
been found up-regulated due to intratumoral hypoxia or 
oncogene signaling, and where it regulates a vast array 
of pro-tumoral responses including metabolism, cell 
survival, neo-angiogenesis, invasion and metastasis [15]. 
For this reason, a number of compounds inhibiting HIF-
1α are under development for treating solid tumors [16]. 
Nonetheless, additional evidence indicates that in specific 
tumor contexts such as in renal cancer HIF-1α may also 
play tumor suppressive functions [17], thus indicating that 
the clinical application of pre-clinical studies with HIF 
inhibitors should be carefully planned.
The role of HIF-1α in leukemia, and in particular in 
acute myeloid leukemia, is only recently beginning to be 
characterized and at the present time it is highly debated. 
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Figure 7: HIF-1α inhibition impairs leukemia homing and progression in MOLM-13 xenograft model in vivo. A. Total 
numbers of human ΔNGFR+ shCTRL or shHIF-1α MOLM-13 cells localizing to the bone marrow (BM) of NSG mice 16 h after tail vein 
injection (over 5 × 106 events; n = 4 for shCTRL, and n=5 shHIF-1α). B. Quantified light output expressed as total flux (photons/seconds) 
from each ROI drawn on the right and left posterior legs of mice injected with MOLM-13 shCTRL and shHIF-1α and co-expressing 
ΔNGFR and luciferase 5 days post leukemia challenge (n=3 for each group) C. Bioluminescence images of mice described in (B). All 
images are plotted with the same scale. D. Total numbers of human ΔNGFR+ MOLM-13 cells transfected with EZN-3088 or EZN-2988 
and localizing to the BM of NSG mice 16 h after tail vein injection (over 5 × 106 events; n=4 for each group). Cells were injected 24 h after 
transfection. E. Quantified light output expressed as total flux (photons/seconds) from each ROI drawn on the right and left posterior legs 
of mice injected with MOLM-13 transfected with EZN-3088 or EZN-2988 and co-expressing ΔNGFR and luciferase 5 days post leukemia 
challenge (n=4 for each group). F. Bioluminescence images of representative mice described in (E). G. Quantified light output expressed 
as total flux (photons/seconds) from each ROI drawn on the right and left posterior legs of mice injected with MOLM-13 transfected with 
EZN-3088 or EZN-2988 and co-expressing ΔNGFR and luciferase 9 days post leukemia challenge (n=4 for each group). H. Kaplan-Meier 
survival curve of NSG mice injected with MOLM-13 transfected with EZN-3088 or EZN-2988 and co-expressing ΔNGFR and luciferase 
(n=4 for each group). Survival curves were analyzed with the Mantel-Cox test.
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HIF-1α was first described as highly expressed in the LICs 
compartment of human AML, identified as CD34+CD38- 
cells, albeit no distinction was made between different sub-
types of AML [20]. By using an inhibitor of HIF-1α, it was 
suggested that HIF-1α is a key regulator of leukemia stem 
cell maintenance in AML [20]. A bias of this study however 
is that LICs were analyzed only in the CD34+CD38- 
fraction, which is not present in all AML, thus suggesting 
that the role of HIF-1α on LICs maintenance should be 
tested more thoroughly in different cell types and different 
patients, especially those with low CD34 expression [30].
After these first indications, we described a pro-
leukemogenic function of HIF-1α in a specific sub-type of 
AML, that is acute promyelocytic leukemia or AML-M3, 
due to a specific functional cooperation of HIF-1α with the 
oncogenic fusion protein PML-RARα [24]. In this context, 
we demonstrated that HIF-1α regulates the clonogenicity 
of leukemic cells, as a read-out of leukemia-initiating 
capacity, but also other pro-leukemogenic functions 
such as bone marrow neo-angiogenesis, chemotaxis and 
leukemia migration/dissemination [24]. Interestingly, a 
study published in the same year challenged the concept 
that HIF-1α promotes leukemogenesis in AML [26]. More 
specifically, genetic deletion of Hif-1α before leukemia 
initiation by different AML oncogenic mutations (AML1-
ETO, MLL-AF9, HOXA9/MEIS1) revealed that loss 
of Hif-1α expression did not delay leukemia initiation 
or progression in any of the genetic models tested, and, 
contrary to previous data, its deletion either did not 
regulate or rather increased leukemia self-renewal in 
secondary transplantation experiments [26]. This study 
however did not address the role of HIF-1α in established 
human leukemia carrying the same oncogenic mutations.
Taken together, these studies present an intricate 
scenario where the role of HIF-1α in AML is still 
controversial and it may change at different stages of 
leukemia development and/or in specific leukemia contexts.
With our current work, by undertaking an in silico 
approach aimed to identify AML patients with deregulated 
hypoxia signaling, we found that besides AML-M3, 
where we had previously implicated HIF factors [24, 
28, 29], patients with the M5 sub-type of AML also 
show significant up-regulation of HIF-1α-target genes 
as compared to all other AML sub-types. Interestingly, 
a number of genes regulating cell migration were found 
up-regulated in AML-M5, which is consistent with the 
propensity of cells of this AML sub-type to infiltrate 
extramedullary sites [7, 8]. Higher expression of these 
genes was validated in primary AML-M5 cells and in cell 
lines, as well as their dependency on HIF-1α expression. 
Interestingly, we observed that within the AML cell 
lines that we analyzed, AML-M3 and AML-M5 cells 
express high levels of HIF-1α protein even in normoxic 
conditions, and this up-regulation does not occur at the 
transcriptional level. Although further studies are needed 
to better understand the molecular basis of this regulation, 
these data are in line with our previous and current 
results showing that HIF-1α is importantly implicated in 
AML-M3 and AML-M5 pathogenesis [24].
In validation of the gene expression results, we 
found that chronic and acute suppression of HIF-1α 
impaired chemotaxis, cell motility and cell invasion in 
cell lines representative of AML-M5. This resulted in 
impaired bone marrow homing and colonization in vivo, 
together with impaired dissemination and engraftment of 
leukemic cells to different organs. The long-term effects 
of HIF-1α suppression in vivo were particularly evident 
upon acute and strong HIF-1α inhibition with a specific 
oligonucleotide. However, as in these circumstances 
we also observed decreased proliferation and increased 
apoptosis compared to chronic and stable HIF-1α 
silencing, we hypothesize that ongoing growth arrest and 
cell death may have contributed to decreased engraftment 
and in vivo leukemia colonization, besides defective cell 
migration. Nonetheless mice survival was only modestly 
prolonged upon acute HIF-1α silencing, as AML-M5 cells 
reacquired HIF-1α expression in vivo, both upon acute and 
chronic HIF-1α silencing, thus indicating that cells with 
reduced HIF-1α expression were being counter selected 
possibly due to increased in vivo selective pressure.
Taken together, these results indicate that in 
AML-M5 HIF-1α plays specific pro-oncogenic functions 
that are mainly related to promoting leukemia cell motility 
and dissemination, but robust HIF-1α suppression may 
exert anti-leukemic functions also by inducing cell death 
and blasts eradication.
Although the M5 sub-type of AML encompasses 
a class of leukemia with different genetic abnormalities, 
including mutations associated with favorable prognosis 
(NPM1), and mutations or chromosomal aberrations 
associated with adverse prognosis (FLT3, DNMT3A, MLL 
fusions) [14], we find that HIF-1α exerts similar effects in 
cell lines representative of genetically different AML-M5, 
as it promotes migration and invasion both in MOLM-13 
cells characterized by FLT3 mutation, and THP-1 cells, 
which harbor an MLL-AF9 translocation (www.dsmz.de). 
Also, we found that patients representative of different 
genetic sub-groups within AML-M5 shared the same up-
regulation of HIF-1α responsive genes irrespective of 
their mutational status (data not shown). Interestingly, we 
did not find any up-regulation of the AML-M5 hypoxia 
sub-signature in M5 leukemic blasts when compared to 
normal monocytes, thus suggesting that up-regulation 
of this specific HIF-1α sub-signature may be a feature 
of monocytes, which is amplified in a leukemic setting 
(data not shown). Taken together, these results suggest 
that differently from AML-M3, where HIF-1α specifically 
cooperates with the fusion protein PML-RARα, in 
AML-M5 HIF-1α may regulate the expression of a set 
of genes that are specifically expressed in monocytic 
progenitors, independently from the genetic insult that led 
to their oncogenic transformation.
Oncotarget53552www.impactjournals.com/oncotarget
In conclusion, our studies demonstrate that HIF-
1α exerts oncogenic functions in AML-M5 and prompt 
future examination on the role of compounds that inhibit 
HIF factors in combination with other therapies for the 
treatment of acute monocytic leukemia.
MATERIALS AND METHODS
AML gene expression data set
We retrieved gene expression profiles from The Cancer 
Genome Atlas (TCGA) Data Portal, (https://tcga-data.nci.
nih.gov/tcga/tcgaHome2.jsp; accession LAML, level 3 
(gene level) correspondent to samples of bone marrow tissue 
from AML patients analyzed using the Affymetrix Human 
Genome U133 Plus 2.0 Array; we considered the samples 
with explicit French-American-British (FAB) classification. 
We analyzed a total of 195 AML patients divided from M0 
to M7 according to the FAB classification. The samples were 
divided as follows: M0 n=17, M1 n=44, M2 n=44, M3 n=20, 
M4 n=42, M5 n=22, M6 n=3 and M7 n=3.
Gene expression analysis
To investigate the contribution of hypoxia-related 
signaling in acute monocytic leukemia (M5) compared 
to other AML sub-types, we used a previously described 
list of bona fide HIF-1α target genes [28] and assessed the 
capability of this signature to discriminate M5 from other 
AML FAB sub-types based on gene expression profiles. 
For this purpose, we applied a supervised approach, the 
Prediction Analysis of Microarray (PAM) [52] available 
in the R environment, in which the nearest shrunken 
centroids classifier is used to evaluate the accuracy of the 
classification and to identify genes whose expressions is 
most distinctive for the M5-class. The complete data set 
of AML samples was visualized according to the selected 
signature in a 3D space of multidimensional scaling (MDS) 
plot using the standard euclidean metric as the measure 
of dissimilarity. The annotation enrichment analysis was 
performed using the David Function Annotation tool [53].
Cell lines and reagents
The human leukemic cell lines KG-1, Kasumi-1, 
HL-60, NB4, MOLM-13, THP-1 and Mono Mac 6 
were maintained in RPMI 1640 and HEK-293T cells in 
IMDM media supplemented with 10% FBS and standard 
antibiotics (Lonza). Primary human umbilical vein 
endothelial cells (HUVEC) were obtained and cultured 
as previously described [54]. All cells were maintained at 
37°C in a humidified atmosphere containing 5% CO2.
EZN-3088 (control LNA-ON for HIF-1α) and 
EZN-2968 (LNA-ON for HIF-1α) [50] were provided 
by Belrose Pharma Inc. and used in accordance with the 
manufacturer’s instructions. MOLM-13, THP-1 and Mono 
Mac 6 cells were transfected with EZN-3088 and EZN-
2968 in an Amaxa™ Nucleofector™ System (Lonza). 
CoCl2, Trypan blue and puromycin were purchased from 
Sigma; SDF-1α (CXCL12) was from Peprotech.
Patients’ samples
Bone marrow samples from AML patients of 
different leukemia sub-type according to the FAB 
classification and containing > 60% primary leukemia 
blasts were collected upon written informed consent 
in accordance with the Declaration of Helsinki by the 
Hematology and Bone Marrow Transplantation Unit at 
IRCCS Ospedale San Raffaele and stored at OSR AML 
Bio Bank. This study was approved by the Institutional 
Review Boards of San Raffaele Scientific Institute, Milan.
Lentiviral vectors
GIPZ HIF-1α or control shRNA plasmids were 
from Open Biosystems. Lentiviral vectors were obtained 
by HEK-293T transfection as previously described [55]. 
MOLM-13, THP-1 and Kasumi-1 cells were transduced 
by spinoculation, selected with puromycin (4 μg/mL, 7 
μg/mL and 1 μg/mL respectively) and sorted for GFP 
expression 2 weeks after transduction (MoFlo XDP, 
Beckman Coulter), leading to a bulk of cells with different 
integrations and GFP levels.
For in vivo experiments, shCTRL and shHIF-
1α MOLM-13 cells were further transduced with a 
bidirectional lentiviral vector co-expressing luciferase and 
truncated nerve growth factor receptor (ΔNGFR) (kindly 
provided by G. Escobar, B. Gentner and L. Naldini, 
unpublished data) and sorted for ΔNGFR (CD271, PE, 
BD Pharmingen) expression 2 weeks after transduction.
For in vivo experiments with LNA-ON (EZN-3088 
and EZN-2968), MOLM-13 cells transduced with the 
bidirectional lentiviral vector co-expressing luciferase and 
ΔNGFR and sorted for ΔNGFR expression 2 weeks after 
transduction, were electroporated with EZN-3088 and 
EZN-2968 and injected in mice after 24 hours.
Real-time PCR
RNA was isolated with the RNeasy mini kit (Qiagen) 
and cDNA was obtained by retro-transcription of 1 μg 
total RNA using Advantage RT for PCR kit (Clontech) 
and analyzed by real-time PCR in 7900 Fast Real-Time 
PCR System (Applied Biosystem). All probes for TaqMan 
assays were purchased from Applied Biosystem. 18S was 
used as internal control.
The relative expression of different cDNAs was 
calculated using the 2−ΔΔCt method with respect to control 
conditions, except for assessing the relative expression of 
LGALS1, S100A4, CAPG, ITGB2, CDKN1A, ZEB2 and 
CXCR4 in primary AML samples and cell lines in Figure 
2 and HIF-1α in Figure 3, which were calculated by the 
2−ΔCt method relative to 18S expression.
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Immunoblot
Total protein extraction from AML cell lines 
was performed by directly incubating cells in SDS-
containing lysis buffer at 95°C for 5 minutes followed 
by brief sonication to extract nuclear proteins. Total 
lysates were resolved by either 7.5% or 4-15% SDS-
PAGE and transferred to a PVDF membrane (Biorad). 
Nonspecific binding was blocked in 5% non-fat milk for 
1 hour at RT and blotted with the following antibodies: 
rabbit polyclonal anti-HIF-1α (Cayman) and mouse 
monoclonal anti-LGALS1 (C-8; Santa Cruz). Mouse 
anti-β-actin (Sigma) was used as internal loading control. 
When indicated, MOLM-13 cells (shCTRL or shHIF1-α) 
where treated for 16 hours with 200 μM CoCl2 before 
lysis. Protein quantification was performed using ImageJ 
software.
Proliferation and apoptosis analysis
MOLM-13 cells (shCTRL and shHIF-1α) were 
plated at 2 × 105 cells/mL into 12 well plates at day 0 
and counted every day for 4 consecutive days using the 
Trypan blue exclusion method. Apoptosis was evaluated 
with Annexin V staining, performed using the PE Annexin 
V Apoptosis detection Kit I (BD Pharmingen) according to 
the manufacturer’s protocol. Cell proliferation upon EZN-
3088 and EZN-2968 electroporation was measured by 
Anti-Human Ki-67 set (BD Pharmingen) according to the 
manufacturer’s instructions 24 hours upon electroporation.
Flow cytometric analysis
For immunophenotypic analysis AML cell lines 
were plated at 4 × 105 cells/mL into 6 well plates and, 
the day after, 1 × 106 cells were collected and stained 
with the following fluorochrome-conjugated anti-human 
antibodies: CXCR4 (PE, R&D Systems) and CD18 
(ITGB2, APC, BD Pharmingen). Staining was performed 
at 4°C for 20 minutes in the dark.
1 × 105 events were acquired at flow cytometer 
(FACS Canto II, Becton Dickinson). Surface expression 
(percentage of positive cells) and MFI (mean fluorescent 
intensity) values were calculated for CXCR4 and ITGB2 
with FlowJo software.
Migration assays
1 × 106 leukemic cells were seeded in the upper 
chamber of a transwell 6.5 mm diameter, 5 μm pore 
(Costar) w/wo 100 ng SDF-1α in the lower chamber. 
Migrated cells were recovered from the lower chamber 
2.5 hours after seeding and counted by flow cytometer 
as the number of cells acquired per minute (FACS Canto 
II, Becton Dickinson). For migration experiments with 
EZN-3088 or EZN-2968 cells were seeded 24 hours after 
electroporation.
Invasion assays
Invasive potential of MOLM-13 and THP-1 cells 
(shCTRL and shHIF-1α) was evaluated using BioCoat™ 
Matrigel Invasion Chamber (Corning). Matrigel coated 
inserts were rehydrated for 2 hours with RPMI 1640. 5 
× 105 cells were resuspended in medium supplemented 
with 0.1% FBS and added to the upper chamber, while 
lower chamber was supplemented with 15% FBS as 
chemoattractant. Cells that crossed the Matrigel-coated 
inserts were recovered from the lower compartments after 
24 hours and counted by flow cytometer as the number 
of cells acquired per minute (FACS Canto II, Becton 
Dickinson).
Transendothelial migration assays
HUVEC cells were seeded in the upper chamber of 
a transwell 6.5 mm diameter, 8 μm pore, (Costar) until 
complete confluence and formation of an endothelial 
monolayer barrier. The lower chamber was filled with 600 
μL of cell culture media. 1.5 × 105 MOLM-13 or THP-1 
cells (shCTRL and shHIF-1α) were seeded on the surface 
of the endothelial monolayer. Cells that crossed the barrier 
were recovered from the lower chambers 24 hours after 
seeding and counted by flow cytometer as the number 
of cells acquired per minute (FACS Canto II, Becton 
Dickinson) to evaluated the transendothelial migration 
activity.
Animal models
NOD/SCID/IL-2rγnull (NSG) immunocompromised 
mice were maintained in a pathogen-free animal facility 
and treated in accordance with European Union guidelines. 
All animal protocols were approved by the Institutional 
Animal Care and Use Commitee (IACUC).
For homing experiments, mice were injected 
intravenously (i.v.) with 5 × 106 MOLM-13 cells 
(shCTRL or shHIF-1α and EZN-3088 or EZN-2968) 
transduced with a bidirectional lentiviral vector co-
expressing luciferase and truncated nerve growth factor 
receptor (ΔNGFR) and euthanized after 16 hours. Bone 
marrow (BM) samples were stained with anti-human 
CD271 (ΔNGFR) antibody (BD Pharmingen) and 5 × 
106 events acquired at flow cytometer (FACS Canto II, 
Becton Dickinson). For survival experiments, mice were 
challenged i.v. with 1 × 105 MOLM-13 cells (shCTRL or 
shHIF-1α and EZN-3088 or EZN-2968) and sacrificed 
when terminally sick. Samples from BM, spleen and 
peripheral blood were stained with anti-human CD33 
and anti-human CD271 (ΔNGFR) antibodies (BD 
Pharmingen) and acquired at flow cytometer (FACS 
Canto II, Becton Dickinson). To further investigate the 
colonization and dissemination of MOLM-13 cells (EZN-
3088 and EZN-2968), NSG mice were injected i.v. with 1 
× 105 cells 24 hours after electroporation, and sacrificed 
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at day 9 and day 15 after leukemia challenge. Samples 
from BM, spleen, peripheral blood, liver, kidneys and 
lungs were stained with anti-human CD33 and anti-
human CD271 (ΔNGFR) antibodies (BD Pharmingen) 
and acquired at flow cytometer (FACS Canto II, Becton 
Dickinson). A separate cohort of animals was used for 
histopathological evaluation of organs colonization, when 
mice were sacrificed because terminally sick. Tissues were 
fixed in 4% formalin, paraffin embedded, cut into 5-μm 
thick sections, and stained with hematoxylin and eosin 
according to standard protocols. Sections were evaluated 
for leukemic dissemination by a certified pathologist.
In vivo bioluminescence imaging
In vivo bioluminescence imaging (BLI) was 
performed by using the IVIS SpectrumCT System (Perkin 
Elmer). This system is equipped with a back-thinned, 
back-illuminated CCD camera cooled at −90°C with a 
quantum efficiency in the visible range above 85%.
Each animal received an intra-peritoneal injection 
of 150 mg luciferin/kg body weight 10 minutes before 
performing BLI. During BLI acquisition, the animals 
were kept at 37°C and under gaseous anesthesia (2–3% 
isoflurane and 1 l/min oxygen).
A set of images was acquired every 2 minutes from 
10 to 20 minutes after luciferin injection in order to detect 
the highest BLI signal. The images were obtained using 
the following settings: exposure time=auto, binning=8, 
f=1 and a field of view equal to 13 cm (field C). Dark 
images were acquired before and then subtracted to 
bioluminescence images, no emission filters were used 
during BLI acquisitions.
BLI image analysis
BLI image analysis was performed by placing 
region of interests (ROI) over the right and left posterior 
legs of the animals as shown in Supplementary Figure 3A. 
The total flux (photons/seconds) was measured in order to 
quantify light emission in each ROI. Images were acquired 
and analyzed using the Living Image 4.5 software (Perkin 
Elmer).
Statistical analysis
Two-sided t-tests were used to validate the 
significance of the data analyzed. A p value of less than 
0.05 was considered statistically significant. All analyses 
were performed with GraphPad Prism software (San 
Diego California). For survival experiments, curves were 
analyzed with the Mantel–Cox test.
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